Focused Wealth Management’s Novavax NVAX Stock Holding History

Focused Wealth Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-500	Closed	-$16K	–	1064
2021 Q4	$16K	Buy	+500	New	+$85.9K	﹤0.01%	518

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Focused Wealth Management's NVAX Position: Q1 2024 in Review

Focused Wealth Management sold out of Novavax (NVAX) in Q1 2024, closing a stake of 33 shares — an estimated $158 sold.

Focused Wealth Management first reported a position in NVAX in Q3 2015 and held it in 13 quarters. The position peaked at $45K in Q1 2022. 201 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.

Focused Wealth Management reported no remaining Novavax position as of Q1 2024 after selling out during the quarter.
Focused Wealth Management sold 33 Novavax shares in Q1 2024, an estimated $158.
Focused Wealth Management first reported a position in Novavax in Q3 2015 and held it in 13 quarters.
Focused Wealth Management's Novavax position peaked at $45K in Q1 2022.
201 funds tracked by Wall St. Rank held Novavax as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.